您的位置：
首页
>
农业专利
>
详情页
ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ПРОИЗВОДНЫХ 4-ПРЕГЕНЕН-11β-17-21-ТРИОЛ-3,20-ДИОНА
- 专利权人:
- АЛЛЕРГАН; ИНК. (US)
- 发明人:
- ЭДЕЛЬМАН Джеффри Л. (US),НЕМЕ Алиссар (US)
- 申请号：
- RU2014123471/15
- 公开号：
- RU2014123471A
- 申请日:
- 2012.11.09
- 申请国别(地区):
- RU
- 年份:
- 2015
- 代理人:
- 摘要：
- A method for treating an ocular disease associated with modulating a glucocorticoid and / or mineralocorticoid receptor, which comprises administering to a patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound selected from: (8S, 9S, 10R, 11S , 13S, 14S, 17R) -17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15, 16,17-tetradecahydro-1H-cyclopenta [a] phenanthren-17-ylphenylacetate (8S, 9S, 10R, 11S, 13S, 14S, 17R) -17-glycoloyl-11-hydroxy-10,13-dimethyl-3- oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-chi (8S, 9S, 10R, 11S, 13S, 14S, 17R) -17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6, 7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta [a] phenanthren-17-ylpropionate (8S, 9S, 10R, 11,13S, 14S, 17R) -17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro -1H-cyclopenta [a] phenanthren-17-yl-octanoate (8S, 9S, 10R, 11S, 13S, 14S, 17R) -17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3 , 6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta [a] phenanthren-17-ylhexanoate (8R, 9R, 10S, 11R, 13R, 14R, 17S) -17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17 -tetradecahydro-1H-cyclopenta [a] phenanthren-17-ylbenzoate (8S, 9S, 10R, 11S, 13S, 14S, 17R) -17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2 , 3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta [a] phenanthren-17-yl heptanoate (8S, 9S, 10R, 11S , 13S, 14S, 17R) -17-glycoloyl-11-guide hydroxy-10,13-dimeth-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta [a] phenanthren- 17-yl 2-methylpropanoate and (8R, 9R, 10S, 11R, 13R, 14R, 17S) -17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro -1H-cyclopenta [a] phenanthren-17-yl rel-cyclopentane carboxylate. The method according to claim 1, wherein said eye disease is selected from an increased intraocular1.
- 来源网站：
- 中国工程科技知识中心
- 来源网址：
- http://www.ckcest.cn/home/
